APO Research

APO RESEARCH · REPORT

Hip Osteoarthritis Pain Drug

Selected research

Market Analysis & Forecast

Global Hip Osteoarthritis Pain Drug Market Analysis and Forecast 2026-2032

Market perspective

The global Hip Osteoarthritis Pain Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Hip Osteoarthritis Pain Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hip Osteoarthritis Pain Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hip Osteoarthritis Pain Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hip Osteoarthritis Pain Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Hip Osteoarthritis Pain Drug include Abiogen Pharma, Almatica Pharma, Astellas Pharma, Horizon Pharma, Iroko Pharmaceuticals, Tide Pharmaceutical, Bayer, Daiichi Sankyo and GlaxoSmithKline, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Hip Osteoarthritis Pain Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hip Osteoarthritis Pain Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Hip Osteoarthritis Pain Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hip Osteoarthritis Pain Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hip Osteoarthritis Pain Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Hip Osteoarthritis Pain Drug sales, projected growth trends, production technology, application and end-user industry.

Hip Osteoarthritis Pain Drug Segment by Company

Abiogen Pharma

Almatica Pharma

Astellas Pharma

Horizon Pharma

Iroko Pharmaceuticals

Tide Pharmaceutical

Bayer

Daiichi Sankyo

GlaxoSmithKline

Pfizer

Hengrui Pharmaceutical

Eli Lilly

Mylan

Novartis

Johnson and Johnson

Sanofi

TEVA

Abbott

Hip Osteoarthritis Pain Drug Segment by Type

Injection

External

Oral

Hip Osteoarthritis Pain Drug Segment by Application

Medical Care

Personal Care

Hip Osteoarthritis Pain Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hip Osteoarthritis Pain Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hip Osteoarthritis Pain Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hip Osteoarthritis Pain Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Hip Osteoarthritis Pain Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Hip Osteoarthritis Pain Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hip Osteoarthritis Pain Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hip Osteoarthritis Pain Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection Major Manufacturers Table 3. External Major Manufacturers Table 4. Oral Major Manufacturers Table 5. Global Hip Osteoarthritis Pain Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Medical Care Major Manufacturers Table 7. Personal Care Major Manufacturers Table 8. Hip Osteoarthritis Pain Drug Industry Trends Table 9. Hip Osteoarthritis Pain Drug Industry Drivers Table 10. Hip Osteoarthritis Pain Drug Industry Opportunities and Challenges Table 11. Hip Osteoarthritis Pain Drug Industry Restraints Table 12. Global Hip Osteoarthritis Pain Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Hip Osteoarthritis Pain Drug Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Hip Osteoarthritis Pain Drug Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2021-2026) Table 16. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2027-2032) Table 17. Global Hip Osteoarthritis Pain Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global Hip Osteoarthritis Pain Drug Sales by Region (2021-2026) & (k units) Table 19. Global Hip Osteoarthritis Pain Drug Sales by Region (2027-2032) & (k units) Table 20. Global Hip Osteoarthritis Pain Drug Sales Market Share by Region (2021-2026) Table 21. Global Hip Osteoarthritis Pain Drug Sales Market Share by Region (2027-2032) Table 22. Global Hip Osteoarthritis Pain Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Hip Osteoarthritis Pain Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers (2021-2026) Table 26. Global Hip Osteoarthritis Pain Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 27. Global Hip Osteoarthritis Pain Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Hip Osteoarthritis Pain Drug Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Hip Osteoarthritis Pain Drug Manufacturers, Product Type & Application Table 30. Global Hip Osteoarthritis Pain Drug Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Hip Osteoarthritis Pain Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Hip Osteoarthritis Pain Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Hip Osteoarthritis Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Hip Osteoarthritis Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2026) Table 37. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2027-2032) Table 38. Global Hip Osteoarthritis Pain Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global Hip Osteoarthritis Pain Drug Sales by Type (2021-2026) & (k units) Table 40. Global Hip Osteoarthritis Pain Drug Sales by Type (2027-2032) & (k units) Table 41. Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2021-2026) Table 42. Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2027-2032) Table 43. Global Hip Osteoarthritis Pain Drug Price by Type (2021-2026) & (US$/unit) Table 44. Global Hip Osteoarthritis Pain Drug Price by Type (2027-2032) & (US$/unit) Table 45. Global Hip Osteoarthritis Pain Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Hip Osteoarthritis Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Hip Osteoarthritis Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2026) Table 49. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2027-2032) Table 50. Global Hip Osteoarthritis Pain Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global Hip Osteoarthritis Pain Drug Sales by Application (2021-2026) & (k units) Table 52. Global Hip Osteoarthritis Pain Drug Sales by Application (2027-2032) & (k units) Table 53. Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2021-2026) Table 54. Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2027-2032) Table 55. Global Hip Osteoarthritis Pain Drug Price by Application (2021-2026) & (US$/unit) Table 56. Global Hip Osteoarthritis Pain Drug Price by Application (2027-2032) & (US$/unit) Table 57. Abiogen Pharma Company Information Table 58. Abiogen Pharma Business Overview Table 59. Abiogen Pharma Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 60. Abiogen Pharma Hip Osteoarthritis Pain Drug Product Portfolio Table 61. Abiogen Pharma Recent Development Table 62. Almatica Pharma Company Information Table 63. Almatica Pharma Business Overview Table 64. Almatica Pharma Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Almatica Pharma Hip Osteoarthritis Pain Drug Product Portfolio Table 66. Almatica Pharma Recent Development Table 67. Astellas Pharma Company Information Table 68. Astellas Pharma Business Overview Table 69. Astellas Pharma Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Astellas Pharma Hip Osteoarthritis Pain Drug Product Portfolio Table 71. Astellas Pharma Recent Development Table 72. Horizon Pharma Company Information Table 73. Horizon Pharma Business Overview Table 74. Horizon Pharma Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Horizon Pharma Hip Osteoarthritis Pain Drug Product Portfolio Table 76. Horizon Pharma Recent Development Table 77. Iroko Pharmaceuticals Company Information Table 78. Iroko Pharmaceuticals Business Overview Table 79. Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product Portfolio Table 81. Iroko Pharmaceuticals Recent Development Table 82. Tide Pharmaceutical Company Information Table 83. Tide Pharmaceutical Business Overview Table 84. Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio Table 86. Tide Pharmaceutical Recent Development Table 87. Bayer Company Information Table 88. Bayer Business Overview Table 89. Bayer Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Bayer Hip Osteoarthritis Pain Drug Product Portfolio Table 91. Bayer Recent Development Table 92. Daiichi Sankyo Company Information Table 93. Daiichi Sankyo Business Overview Table 94. Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Daiichi Sankyo Hip Osteoarthritis Pain Drug Product Portfolio Table 96. Daiichi Sankyo Recent Development Table 97. GlaxoSmithKline Company Information Table 98. GlaxoSmithKline Business Overview Table 99. GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline Hip Osteoarthritis Pain Drug Product Portfolio Table 101. GlaxoSmithKline Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Pfizer Hip Osteoarthritis Pain Drug Product Portfolio Table 106. Pfizer Recent Development Table 107. Hengrui Pharmaceutical Company Information Table 108. Hengrui Pharmaceutical Business Overview Table 109. Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio Table 111. Hengrui Pharmaceutical Recent Development Table 112. Eli Lilly Company Information Table 113. Eli Lilly Business Overview Table 114. Eli Lilly Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Eli Lilly Hip Osteoarthritis Pain Drug Product Portfolio Table 116. Eli Lilly Recent Development Table 117. Mylan Company Information Table 118. Mylan Business Overview Table 119. Mylan Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Mylan Hip Osteoarthritis Pain Drug Product Portfolio Table 121. Mylan Recent Development Table 122. Novartis Company Information Table 123. Novartis Business Overview Table 124. Novartis Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Novartis Hip Osteoarthritis Pain Drug Product Portfolio Table 126. Novartis Recent Development Table 127. Johnson and Johnson Company Information Table 128. Johnson and Johnson Business Overview Table 129. Johnson and Johnson Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Johnson and Johnson Hip Osteoarthritis Pain Drug Product Portfolio Table 131. Johnson and Johnson Recent Development Table 132. Sanofi Company Information Table 133. Sanofi Business Overview Table 134. Sanofi Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Sanofi Hip Osteoarthritis Pain Drug Product Portfolio Table 136. Sanofi Recent Development Table 137. TEVA Company Information Table 138. TEVA Business Overview Table 139. TEVA Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 140. TEVA Hip Osteoarthritis Pain Drug Product Portfolio Table 141. TEVA Recent Development Table 142. Abbott Company Information Table 143. Abbott Business Overview Table 144. Abbott Hip Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 145. Abbott Hip Osteoarthritis Pain Drug Product Portfolio Table 146. Abbott Recent Development Table 147. North America Hip Osteoarthritis Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 148. North America Hip Osteoarthritis Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 149. North America Hip Osteoarthritis Pain Drug Sales by Type (2021-2026) & (k units) Table 150. North America Hip Osteoarthritis Pain Drug Sales by Type (2027-2032) & (k units) Table 151. North America Hip Osteoarthritis Pain Drug Sales Price by Type (2021-2026) & (US$/unit) Table 152. North America Hip Osteoarthritis Pain Drug Sales Price by Type (2027-2032) & (US$/unit) Table 153. North America Hip Osteoarthritis Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Hip Osteoarthritis Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Hip Osteoarthritis Pain Drug Sales by Application (2021-2026) & (k units) Table 156. North America Hip Osteoarthritis Pain Drug Sales by Application (2027-2032) & (k units) Table 157. North America Hip Osteoarthritis Pain Drug Sales Price by Application (2021-2026) & (US$/unit) Table 158. North America Hip Osteoarthritis Pain Drug Sales Price by Application (2027-2032) & (US$/unit) Table 159. North America Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. North America Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. North America Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. North America Hip Osteoarthritis Pain Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 163. North America Hip Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 164. North America Hip Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 165. North America Hip Osteoarthritis Pain Drug Sales Price by Country (2021-2026) & (US$/unit) Table 166. North America Hip Osteoarthritis Pain Drug Sales Price by Country (2027-2032) & (US$/unit) Table 167. United States Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 168. Canada Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 169. Mexico Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 170. Europe Hip Osteoarthritis Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 171. Europe Hip Osteoarthritis Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 172. Europe Hip Osteoarthritis Pain Drug Sales by Type (2021-2026) & (k units) Table 173. Europe Hip Osteoarthritis Pain Drug Sales by Type (2027-2032) & (k units) Table 174. Europe Hip Osteoarthritis Pain Drug Sales Price by Type (2021-2026) & (US$/unit) Table 175. Europe Hip Osteoarthritis Pain Drug Sales Price by Type (2027-2032) & (US$/unit) Table 176. Europe Hip Osteoarthritis Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 177. Europe Hip Osteoarthritis Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 178. Europe Hip Osteoarthritis Pain Drug Sales by Application (2021-2026) & (k units) Table 179. Europe Hip Osteoarthritis Pain Drug Sales by Application (2027-2032) & (k units) Table 180. Europe Hip Osteoarthritis Pain Drug Sales Price by Application (2021-2026) & (US$/unit) Table 181. Europe Hip Osteoarthritis Pain Drug Sales Price by Application (2027-2032) & (US$/unit) Table 182. Europe Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. Europe Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. Europe Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. Europe Hip Osteoarthritis Pain Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 186. Europe Hip Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 187. Europe Hip Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 188. Europe Hip Osteoarthritis Pain Drug Sales Price by Country (2021-2026) & (US$/unit) Table 189. Europe Hip Osteoarthritis Pain Drug Sales Price by Country (2027-2032) & (US$/unit) Table 190. Germany Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 191. France Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 192. U.K. Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 193. Italy Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 194. Russia Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 195. Spain Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 196. Netherlands Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 197. Switzerland Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 198. Sweden Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 199. Poland Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 200. China Hip Osteoarthritis Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 201. China Hip Osteoarthritis Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 202. China Hip Osteoarthritis Pain Drug Sales by Type (2021-2026) & (k units) Table 203. China Hip Osteoarthritis Pain Drug Sales by Type (2027-2032) & (k units) Table 204. China Hip Osteoarthritis Pain Drug Sales Price by Type (2021-2026) & (US$/unit) Table 205. China Hip Osteoarthritis Pain Drug Sales Price by Type (2027-2032) & (US$/unit) Table 206. China Hip Osteoarthritis Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 207. China Hip Osteoarthritis Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 208. China Hip Osteoarthritis Pain Drug Sales by Application (2021-2026) & (k units) Table 209. China Hip Osteoarthritis Pain Drug Sales by Application (2027-2032) & (k units) Table 210. China Hip Osteoarthritis Pain Drug Sales Price by Application (2021-2026) & (US$/unit) Table 211. China Hip Osteoarthritis Pain Drug Sales Price by Application (2027-2032) & (US$/unit) Table 212. Asia Hip Osteoarthritis Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 213. Asia Hip Osteoarthritis Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 214. Asia Hip Osteoarthritis Pain Drug Sales by Type (2021-2026) & (k units) Table 215. Asia Hip Osteoarthritis Pain Drug Sales by Type (2027-2032) & (k units) Table 216. Asia Hip Osteoarthritis Pain Drug Sales Price by Type (2021-2026) & (US$/unit) Table 217. Asia Hip Osteoarthritis Pain Drug Sales Price by Type (2027-2032) & (US$/unit) Table 218. Asia Hip Osteoarthritis Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 219. Asia Hip Osteoarthritis Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 220. Asia Hip Osteoarthritis Pain Drug Sales by Application (2021-2026) & (k units) Table 221. Asia Hip Osteoarthritis Pain Drug Sales by Application (2027-2032) & (k units) Table 222. Asia Hip Osteoarthritis Pain Drug Sales Price by Application (2021-2026) & (US$/unit) Table 223. Asia Hip Osteoarthritis Pain Drug Sales Price by Application (2027-2032) & (US$/unit) Table 224. Asia Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 225. Asia Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 226. Asia Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 227. Asia Hip Osteoarthritis Pain Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 228. Asia Hip Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 229. Asia Hip Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 230. Asia Hip Osteoarthritis Pain Drug Sales Price by Country (2021-2026) & (US$/unit) Table 231. Asia Hip Osteoarthritis Pain Drug Sales Price by Country (2027-2032) & (US$/unit) Table 232. Japan Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 233. South Korea Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 234. India Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 235. Australia Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 236. Taiwan Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 237. Southeast Asia Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 238. SAMEA Hip Osteoarthritis Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 239. SAMEA Hip Osteoarthritis Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 240. SAMEA Hip Osteoarthritis Pain Drug Sales by Type (2021-2026) & (k units) Table 241. SAMEA Hip Osteoarthritis Pain Drug Sales by Type (2027-2032) & (k units) Table 242. SAMEA Hip Osteoarthritis Pain Drug Sales Price by Type (2021-2026) & (US$/unit) Table 243. SAMEA Hip Osteoarthritis Pain Drug Sales Price by Type (2027-2032) & (US$/unit) Table 244. SAMEA Hip Osteoarthritis Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 245. SAMEA Hip Osteoarthritis Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 246. SAMEA Hip Osteoarthritis Pain Drug Sales by Application (2021-2026) & (k units) Table 247. SAMEA Hip Osteoarthritis Pain Drug Sales by Application (2027-2032) & (k units) Table 248. SAMEA Hip Osteoarthritis Pain Drug Sales Price by Application (2021-2026) & (US$/unit) Table 249. SAMEA Hip Osteoarthritis Pain Drug Sales Price by Application (2027-2032) & (US$/unit) Table 250. SAMEA Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 251. SAMEA Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 252. SAMEA Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 253. SAMEA Hip Osteoarthritis Pain Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 254. SAMEA Hip Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 255. SAMEA Hip Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 256. SAMEA Hip Osteoarthritis Pain Drug Sales Price by Country (2021-2026) & (US$/unit) Table 257. SAMEA Hip Osteoarthritis Pain Drug Sales Price by Country (2027-2032) & (US$/unit) Table 258. Brazil Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 259. Argentina Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 260. Chile Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 261. Colombia Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 262. Peru Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 263. Saudi Arabia Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 264. Israel Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 265. UAE Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 266. Turkey Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 267. Iran Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 268. Egypt Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Table 269. Key Raw Materials Table 270. Raw Materials Key Suppliers Table 271. Hip Osteoarthritis Pain Drug Distributors List Table 272. Hip Osteoarthritis Pain Drug Customers List Table 273. Research Programs/Design for This Report Table 274. Authors List of This Report Table 275. Secondary Sources Table 276. Primary Sources List of Figures Figure 1. Hip Osteoarthritis Pain Drug Image Figure 2. Global Hip Osteoarthritis Pain Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hip Osteoarthritis Pain Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection Image Figure 5. External Image Figure 6. Oral Image Figure 7. Global Hip Osteoarthritis Pain Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Hip Osteoarthritis Pain Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Medical Care Image Figure 10. Personal Care Image Figure 11. Global Hip Osteoarthritis Pain Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Figure 13. Global Hip Osteoarthritis Pain Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2021-2032) Figure 16. Global Hip Osteoarthritis Pain Drug Sales (2021-2032) & (k units) Figure 17. Global Hip Osteoarthritis Pain Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global Hip Osteoarthritis Pain Drug Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Hip Osteoarthritis Pain Drug Sales YoY (2021-2032) & (k units) Figure 20. Europe Hip Osteoarthritis Pain Drug Sales YoY (2021-2032) & (k units) Figure 21. China Hip Osteoarthritis Pain Drug Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) Hip Osteoarthritis Pain Drug Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa Hip Osteoarthritis Pain Drug Sales YoY (2021-2032) & (k units) Figure 24. Global Hip Osteoarthritis Pain Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Hip Osteoarthritis Pain Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Hip Osteoarthritis Pain Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2032) Figure 30. Global Hip Osteoarthritis Pain Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Hip Osteoarthritis Pain Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2021-2032) Figure 33. Global Hip Osteoarthritis Pain Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2032) Figure 36. Global Hip Osteoarthritis Pain Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 37. Global Hip Osteoarthritis Pain Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2021-2032) Figure 39. North America Hip Osteoarthritis Pain Drug Revenue Share by Type (2021-2032) Figure 40. North America Hip Osteoarthritis Pain Drug Sales Share by Type (2021-2032) Figure 41. North America Hip Osteoarthritis Pain Drug Revenue Share by Application (2021-2032) Figure 42. North America Hip Osteoarthritis Pain Drug Sales Share by Application (2021-2032) Figure 43. North America Hip Osteoarthritis Pain Drug Revenue Share by Country (2021-2032) Figure 44. North America Hip Osteoarthritis Pain Drug Sales Share by Country (2021-2032) Figure 45. Europe Hip Osteoarthritis Pain Drug Revenue Share by Type (2021-2032) Figure 46. Europe Hip Osteoarthritis Pain Drug Sales Share by Type (2021-2032) Figure 47. Europe Hip Osteoarthritis Pain Drug Revenue Share by Application (2021-2032) Figure 48. Europe Hip Osteoarthritis Pain Drug Sales Share by Application (2021-2032) Figure 49. Europe Hip Osteoarthritis Pain Drug Revenue Share by Country (2021-2032) Figure 50. Europe Hip Osteoarthritis Pain Drug Sales Share by Country (2021-2032) Figure 51. China Hip Osteoarthritis Pain Drug Revenue Share by Type (2021-2032) Figure 52. China Hip Osteoarthritis Pain Drug Sales Share by Type (2021-2032) Figure 53. China Hip Osteoarthritis Pain Drug Revenue Share by Application (2021-2032) Figure 54. China Hip Osteoarthritis Pain Drug Sales Share by Application (2021-2032) Figure 55. Asia Hip Osteoarthritis Pain Drug Revenue Share by Type (2021-2032) Figure 56. Asia Hip Osteoarthritis Pain Drug Sales Share by Type (2021-2032) Figure 57. Asia Hip Osteoarthritis Pain Drug Revenue Share by Application (2021-2032) Figure 58. Asia Hip Osteoarthritis Pain Drug Sales Share by Application (2021-2032) Figure 59. Asia Hip Osteoarthritis Pain Drug Revenue Share by Country (2021-2032) Figure 60. Asia Hip Osteoarthritis Pain Drug Sales Share by Country (2021-2032) Figure 61. SAMEA Hip Osteoarthritis Pain Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA Hip Osteoarthritis Pain Drug Sales Share by Type (2021-2032) Figure 63. SAMEA Hip Osteoarthritis Pain Drug Revenue Share by Application (2021-2032) Figure 64. SAMEA Hip Osteoarthritis Pain Drug Sales Share by Application (2021-2032) Figure 65. SAMEA Hip Osteoarthritis Pain Drug Revenue Share by Country (2021-2032) Figure 66. SAMEA Hip Osteoarthritis Pain Drug Sales Share by Country (2021-2032) Figure 67. Hip Osteoarthritis Pain Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Hip Osteoarthritis Pain Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • External
  • Oral
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Abiogen Pharma
  • Almatica Pharma
  • Astellas Pharma
  • Horizon Pharma
  • Iroko Pharmaceuticals
  • Tide Pharmaceutical
  • Bayer
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Pfizer
  • Hengrui Pharmaceutical
  • Eli Lilly
  • Mylan
  • Novartis
  • Johnson and Johnson
  • Sanofi
  • TEVA
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hip Osteoarthritis Pain Drug Market by Type
  3. 1.2.1 Global Hip Osteoarthritis Pain Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 External
  6. 1.2.4 Oral
  7. 1.3 Hip Osteoarthritis Pain Drug Market by Application
  8. 1.3.1 Global Hip Osteoarthritis Pain Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Medical Care
  10. 1.3.3 Personal Care
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Hip Osteoarthritis Pain Drug Market Dynamics
  1. 2.1 Hip Osteoarthritis Pain Drug Industry Trends
  2. 2.2 Hip Osteoarthritis Pain Drug Industry Drivers
  3. 2.3 Hip Osteoarthritis Pain Drug Industry Opportunities and Challenges
  4. 2.4 Hip Osteoarthritis Pain Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Hip Osteoarthritis Pain Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Hip Osteoarthritis Pain Drug Revenue by Region
  3. 3.2.1 Global Hip Osteoarthritis Pain Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hip Osteoarthritis Pain Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Hip Osteoarthritis Pain Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Hip Osteoarthritis Pain Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Hip Osteoarthritis Pain Drug Sales by Region
  9. 3.4.1 Global Hip Osteoarthritis Pain Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Hip Osteoarthritis Pain Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Hip Osteoarthritis Pain Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Hip Osteoarthritis Pain Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Hip Osteoarthritis Pain Drug Revenue by Manufacturers
  2. 4.1.1 Global Hip Osteoarthritis Pain Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Hip Osteoarthritis Pain Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hip Osteoarthritis Pain Drug Sales by Manufacturers
  6. 4.2.1 Global Hip Osteoarthritis Pain Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Hip Osteoarthritis Pain Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Hip Osteoarthritis Pain Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Hip Osteoarthritis Pain Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Hip Osteoarthritis Pain Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Hip Osteoarthritis Pain Drug Manufacturers, Product Type & Application
  13. 4.7 Global Hip Osteoarthritis Pain Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Hip Osteoarthritis Pain Drug Market CR5 and HHI
  16. 4.8.2 2025 Hip Osteoarthritis Pain Drug Tier 1, Tier 2, and Tier 3
5 Hip Osteoarthritis Pain Drug Market by Type
  1. 5.1 Global Hip Osteoarthritis Pain Drug Revenue by Type
  2. 5.1.1 Global Hip Osteoarthritis Pain Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Hip Osteoarthritis Pain Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Hip Osteoarthritis Pain Drug Sales by Type
  6. 5.2.1 Global Hip Osteoarthritis Pain Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hip Osteoarthritis Pain Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Hip Osteoarthritis Pain Drug Price by Type
6 Hip Osteoarthritis Pain Drug Market by Application
  1. 6.1 Global Hip Osteoarthritis Pain Drug Revenue by Application
  2. 6.1.1 Global Hip Osteoarthritis Pain Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Hip Osteoarthritis Pain Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Hip Osteoarthritis Pain Drug Sales by Application
  6. 6.2.1 Global Hip Osteoarthritis Pain Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Hip Osteoarthritis Pain Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Hip Osteoarthritis Pain Drug Price by Application
7 Company Profiles
  1. 7.1 Abiogen Pharma
  2. 7.1.1 Abiogen Pharma Company Information
  3. 7.1.2 Abiogen Pharma Business Overview
  4. 7.1.3 Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Abiogen Pharma Hip Osteoarthritis Pain Drug Product Portfolio
  6. 7.1.5 Abiogen Pharma Recent Developments
  7. 7.2 Almatica Pharma
  8. 7.2.1 Almatica Pharma Company Information
  9. 7.2.2 Almatica Pharma Business Overview
  10. 7.2.3 Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Almatica Pharma Hip Osteoarthritis Pain Drug Product Portfolio
  12. 7.2.5 Almatica Pharma Recent Developments
  13. 7.3 Astellas Pharma
  14. 7.3.1 Astellas Pharma Company Information
  15. 7.3.2 Astellas Pharma Business Overview
  16. 7.3.3 Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Astellas Pharma Hip Osteoarthritis Pain Drug Product Portfolio
  18. 7.3.5 Astellas Pharma Recent Developments
  19. 7.4 Horizon Pharma
  20. 7.4.1 Horizon Pharma Company Information
  21. 7.4.2 Horizon Pharma Business Overview
  22. 7.4.3 Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Horizon Pharma Hip Osteoarthritis Pain Drug Product Portfolio
  24. 7.4.5 Horizon Pharma Recent Developments
  25. 7.5 Iroko Pharmaceuticals
  26. 7.5.1 Iroko Pharmaceuticals Company Information
  27. 7.5.2 Iroko Pharmaceuticals Business Overview
  28. 7.5.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product Portfolio
  30. 7.5.5 Iroko Pharmaceuticals Recent Developments
  31. 7.6 Tide Pharmaceutical
  32. 7.6.1 Tide Pharmaceutical Company Information
  33. 7.6.2 Tide Pharmaceutical Business Overview
  34. 7.6.3 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio
  36. 7.6.5 Tide Pharmaceutical Recent Developments
  37. 7.7 Bayer
  38. 7.7.1 Bayer Company Information
  39. 7.7.2 Bayer Business Overview
  40. 7.7.3 Bayer Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Bayer Hip Osteoarthritis Pain Drug Product Portfolio
  42. 7.7.5 Bayer Recent Developments
  43. 7.8 Daiichi Sankyo
  44. 7.8.1 Daiichi Sankyo Company Information
  45. 7.8.2 Daiichi Sankyo Business Overview
  46. 7.8.3 Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Hip Osteoarthritis Pain Drug Product Portfolio
  48. 7.8.5 Daiichi Sankyo Recent Developments
  49. 7.9 GlaxoSmithKline
  50. 7.9.1 GlaxoSmithKline Company Information
  51. 7.9.2 GlaxoSmithKline Business Overview
  52. 7.9.3 GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 GlaxoSmithKline Hip Osteoarthritis Pain Drug Product Portfolio
  54. 7.9.5 GlaxoSmithKline Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Hip Osteoarthritis Pain Drug Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 Hengrui Pharmaceutical
  62. 7.11.1 Hengrui Pharmaceutical Company Information
  63. 7.11.2 Hengrui Pharmaceutical Business Overview
  64. 7.11.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio
  66. 7.11.5 Hengrui Pharmaceutical Recent Developments
  67. 7.12 Eli Lilly
  68. 7.12.1 Eli Lilly Company Information
  69. 7.12.2 Eli Lilly Business Overview
  70. 7.12.3 Eli Lilly Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Eli Lilly Hip Osteoarthritis Pain Drug Product Portfolio
  72. 7.12.5 Eli Lilly Recent Developments
  73. 7.13 Mylan
  74. 7.13.1 Mylan Company Information
  75. 7.13.2 Mylan Business Overview
  76. 7.13.3 Mylan Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Mylan Hip Osteoarthritis Pain Drug Product Portfolio
  78. 7.13.5 Mylan Recent Developments
  79. 7.14 Novartis
  80. 7.14.1 Novartis Company Information
  81. 7.14.2 Novartis Business Overview
  82. 7.14.3 Novartis Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Novartis Hip Osteoarthritis Pain Drug Product Portfolio
  84. 7.14.5 Novartis Recent Developments
  85. 7.15 Johnson and Johnson
  86. 7.15.1 Johnson and Johnson Company Information
  87. 7.15.2 Johnson and Johnson Business Overview
  88. 7.15.3 Johnson and Johnson Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Johnson and Johnson Hip Osteoarthritis Pain Drug Product Portfolio
  90. 7.15.5 Johnson and Johnson Recent Developments
  91. 7.16 Sanofi
  92. 7.16.1 Sanofi Company Information
  93. 7.16.2 Sanofi Business Overview
  94. 7.16.3 Sanofi Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Sanofi Hip Osteoarthritis Pain Drug Product Portfolio
  96. 7.16.5 Sanofi Recent Developments
  97. 7.17 TEVA
  98. 7.17.1 TEVA Company Information
  99. 7.17.2 TEVA Business Overview
  100. 7.17.3 TEVA Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 TEVA Hip Osteoarthritis Pain Drug Product Portfolio
  102. 7.17.5 TEVA Recent Developments
  103. 7.18 Abbott
  104. 7.18.1 Abbott Company Information
  105. 7.18.2 Abbott Business Overview
  106. 7.18.3 Abbott Hip Osteoarthritis Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Abbott Hip Osteoarthritis Pain Drug Product Portfolio
  108. 7.18.5 Abbott Recent Developments
8 North America
  1. 8.1 North America Hip Osteoarthritis Pain Drug Market Size by Type
  2. 8.1.1 North America Hip Osteoarthritis Pain Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Hip Osteoarthritis Pain Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Hip Osteoarthritis Pain Drug Price by Type (2021-2032)
  5. 8.2 North America Hip Osteoarthritis Pain Drug Market Size by Application
  6. 8.2.1 North America Hip Osteoarthritis Pain Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Hip Osteoarthritis Pain Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Hip Osteoarthritis Pain Drug Price by Application (2021-2032)
  9. 8.3 North America Hip Osteoarthritis Pain Drug Market Size by Country
  10. 8.3.1 North America Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Hip Osteoarthritis Pain Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Hip Osteoarthritis Pain Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Hip Osteoarthritis Pain Drug Market Size by Type
  2. 9.1.1 Europe Hip Osteoarthritis Pain Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Hip Osteoarthritis Pain Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Hip Osteoarthritis Pain Drug Price by Type (2021-2032)
  5. 9.2 Europe Hip Osteoarthritis Pain Drug Market Size by Application
  6. 9.2.1 Europe Hip Osteoarthritis Pain Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Hip Osteoarthritis Pain Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Hip Osteoarthritis Pain Drug Price by Application (2021-2032)
  9. 9.3 Europe Hip Osteoarthritis Pain Drug Market Size by Country
  10. 9.3.1 Europe Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Hip Osteoarthritis Pain Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Hip Osteoarthritis Pain Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Hip Osteoarthritis Pain Drug Market Size by Type
  2. 10.1.1 China Hip Osteoarthritis Pain Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Hip Osteoarthritis Pain Drug Sales by Type (2021-2032)
  4. 10.1.3 China Hip Osteoarthritis Pain Drug Price by Type (2021-2032)
  5. 10.2 China Hip Osteoarthritis Pain Drug Market Size by Application
  6. 10.2.1 China Hip Osteoarthritis Pain Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Hip Osteoarthritis Pain Drug Sales by Application (2021-2032)
  8. 10.2.3 China Hip Osteoarthritis Pain Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hip Osteoarthritis Pain Drug Market Size by Type
  2. 11.1.1 Asia Hip Osteoarthritis Pain Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Hip Osteoarthritis Pain Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Hip Osteoarthritis Pain Drug Price by Type (2021-2032)
  5. 11.2 Asia Hip Osteoarthritis Pain Drug Market Size by Application
  6. 11.2.1 Asia Hip Osteoarthritis Pain Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Hip Osteoarthritis Pain Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Hip Osteoarthritis Pain Drug Price by Application (2021-2032)
  9. 11.3 Asia Hip Osteoarthritis Pain Drug Market Size by Country
  10. 11.3.1 Asia Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Hip Osteoarthritis Pain Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Hip Osteoarthritis Pain Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hip Osteoarthritis Pain Drug Market Size by Type
  2. 12.1.1 SAMEA Hip Osteoarthritis Pain Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Hip Osteoarthritis Pain Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Hip Osteoarthritis Pain Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Hip Osteoarthritis Pain Drug Market Size by Application
  6. 12.2.1 SAMEA Hip Osteoarthritis Pain Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Hip Osteoarthritis Pain Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Hip Osteoarthritis Pain Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Hip Osteoarthritis Pain Drug Market Size by Country
  10. 12.3.1 SAMEA Hip Osteoarthritis Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Hip Osteoarthritis Pain Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Hip Osteoarthritis Pain Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Hip Osteoarthritis Pain Drug Value Chain Analysis
  2. 13.1.1 Hip Osteoarthritis Pain Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Hip Osteoarthritis Pain Drug Production Mode & Process
  6. 13.2 Hip Osteoarthritis Pain Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Hip Osteoarthritis Pain Drug Distributors
  9. 13.2.3 Hip Osteoarthritis Pain Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research